RE:RE:CD8+ TiLs and T-cell exhaustionIovance Biotherapeutics' PDUFA date of February 24, 2024 determining the approval of its tumor infiltrating lymphocyte (TIL) therapy will serve to confirm ONCY's pelareorep critical effect on the increase of CD8+ TiLs cells as significant mediators of cytotoxic effector function in the treatment of cancer,
As posted earlier, high levels of PD-1 expression contribute to the characteristic dysfunction seen in exhausted CD8+ TiL cells. Correspondingly, in human tumors, a higher proportion of progenitor exhausted cells was associated with a greater likelihood of response to checkpoint blockade. While PD-1 blockade therapies have been successful in multiple tumor types, their effectiveness has been limited to between 10-20% of the patients treated.
https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35853034